Spero Therapeutics, Inc. (SPRO) - 10-K Summary
Business Context and Reporting Period
Company: Spero Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Spero is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company has no approved products and has not generated revenue from product sales. Its primary asset is tebipenem HBr, an oral carbapenem in Phase 3 development for complicated urinary tract infections (cUTIs), partnered with GlaxoSmithKline (GSK). The company recently suspended development of its SPR720 program and discontinued its SPR206 program to reallocate resources.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Total Revenues | $48.0 | $103.8 |
| Net Loss | $(68.6) | $22.8 (Net Income) |
| Operating Expenses | $121.3 | $82.3 |
| Research & Development (R&D) | $96.8 | $51.4 |
| Cash and Cash Equivalents | $52.9 | $76.3 |
| Accumulated Deficit | $(459.6) | $(391.1) |
Liquidity: As of December 31, 2024, the company held $52.9 million in cash and cash equivalents. Management estimates a cash runway into the second quarter of 2026, contingent on earned and non-contingent milestone payments from GSK and government grants. The auditor has expressed substantial doubt about the company's ability to continue as a going concern.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $55.8 million (54%) to $48.0 million. This was primarily due to a $68.8 million decrease in collaboration revenue from GSK, as 2023 included significant milestone recognitions ($95.8 million) that were not repeated in 2024. Grant revenue increased by $13.5 million to $20.6 million, driven by BARDA funding for tebipenem HBr.
- Net Loss vs. Income: The company swung from a net income of $22.8 million in 2023 to a net loss of $68.6 million in 2024. This shift was driven by higher R&D expenses and lower collaboration revenue.
- R&D Expense Increase: R&D expenses rose by $45.3 million (88%) to $96.8 million. The increase was largely attributable to the initiation of the pivotal Phase 3 PIVOT-PO clinical trial for tebipenem HBr and continued activity for SPR720 prior to its suspension.
- Restructuring: The company incurred $0.9 million in restructuring charges in 2024 related to a workforce reduction of approximately 39% announced in October 2024.
Guidance, Outlook, Risks, and Unusual Items
Strategic Reprioritization:
- tebipenem HBr: The primary focus. The Phase 3 PIVOT-PO trial is ongoing, with an interim analysis expected in Q2 2025. The company is responsible for the trial execution and costs, while GSK handles commercialization.
- SPR720: Development suspended in October 2024 after the Phase 2a trial failed to meet its primary endpoint and showed safety signals (hepatotoxicity). The company is analyzing remaining data to determine next steps.
- SPR206: Development discontinued in March 2025.
Legal and Regulatory Risks:
- SEC Investigation: The company received a "Wells Notice" from the SEC in January 2025 regarding potential civil enforcement actions related to disclosures made in 2022 concerning tebipenem HBr. Former CEO Ankit Mahadevia and former CFO Satyavrat Shukla are also subjects of the notice. The company denies wrongdoing.
- Nasdaq Compliance: The company received a deficiency letter from Nasdaq in February 2025 for failing to maintain a $1.00 minimum bid price. It has until August 25, 2025, to regain compliance or face delisting.
- Going Concern: Substantial doubt exists regarding the company's ability to continue operations without additional capital. Future funding will likely require equity/debt financings or new collaborations.
Leadership Changes: In January 2025, Esther Rajavelu was appointed Interim CEO and President while the former CEO and CFO were placed on administrative leave pending the resolution of the SEC investigation.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $52.9 million cash balance plus expected GSK milestones to fund operations through Q2 2026, especially given the "substantial doubt" going concern warning.
- PIVOT-PO Trial Status: Monitor the timeline and results of the interim analysis for the tebipenem HBr Phase 3 trial, expected in Q2 2025, as this is the company's primary value driver.
- SEC Wells Notice Outcome: Track the resolution of the SEC investigation and Wells Notice, which could result in penalties, disgorgement, or officer bans, impacting the company's reputation and operations.
- Nasdaq Listing Status: Confirm whether the company regains compliance with the $1.00 minimum bid price requirement by August 25, 2025, to avoid delisting.
- SPR720 Future: Assess the company's decision on the suspended SPR720 program following the completion of data analysis, as this could impact future pipeline depth.